ArticleCancer epidemiology2017
Survival after recurrence of stage I-III breast, colorectal, or lung cancer.
Article in Cancer epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Economic evaluation of artificial intelligence for cancer detection in the UK breast screening programme.British journal of cancer · 2026Article
- Patterns of recurrence among adults diagnosed with screen-detected lung cancer.Cancer epidemiology · 2025Article
- Association of systemic therapy with survival among adults with advanced non-small cell lung cancer.Translational lung cancer research · 2025Article
- Risk factors for recurrence in stage I colorectal cancer after curative resection: a systematic review and meta-analysis.Annals of surgical treatment and research · 2025Article
- Influence of the initial recurrence site on prognosis after radical surgery for colorectal cancer: a retrospective cohort study.World journal of surgical oncology · 2023Article
- Identification of high-risk stage I colon and rectal cancer patients: a retrospective analysis of a large Japanese cohort.International journal of colorectal disease · 2022Article
- Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation.European radiology · 2022Article
- The Influence of Analgesic Modalities on Postoperative Cancer Recurrence.Anesthesiology and pain medicine · 2022Review
- Regarding the Utility of Unstructured Data and Natural Language Processing for Identification of Breast Cancer Recurrence.JCO clinical cancer informatics · 2021Article
- CD8Clinical & translational immunology · 2020Article
- Melanoma incidence, recurrence, and mortality in an integrated healthcare system: A retrospective cohort study.Cancer medicine · 2019Article
- Does adjuvant therapy reduce postmetastatic survival?Annals of oncology : official journal of the European Society for Medical Oncology · 2019Article
- Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease.Journal of oncology practice · 2019Article
- Performance of Cancer Recurrence Algorithms After Coding Scheme Switch From International Classification of Diseases 9th Revision to International Classification of Diseases 10th Revision.JCO clinical cancer informatics · 2019Article
- Comparing Survival After Recurrent vs De Novo Stage IV Advanced Breast, Lung, and Colorectal Cancer.JNCI cancer spectrum · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe experiences of patients with recurrent cancer are assumed to reflect those of patients with de novo stage IV disease; yet, little is truly known because most registries lack recurrence status. Using two databases with excellent recurrence and death information, we examined determinants of survival duration after recurrence of breast (BC), colorectal (CRC), and lung cancers (LC).
methodsRecurrence status was abstracted from the medical records of patients who participated in the Cancer Care Outcomes Research and Surveillance study and who received care at two Cancer Research Network sites-the Colorado and Northwest regions of Kaiser Permanente. The analysis included 1653 patients who developed recurrence after completing definitive therapy for stages I-III cancer. Multivariable modeling identified independent determinants of survival duration after recurrence, controlling for other factors.
resultsThrough 60 months' average follow-up, survival after recurrence for BC, CRC, and LC were 28.4, 23.1 and 16.1 months, respectively. Several factors were independently associated with shorter survival for all three cancers, including higher initial stage (III vs. I: BC -9.9 months; CRC -6.9 months; LC -7.4 months; P≤0.01). Factors associated with shorter survival for selected cancers included: distant/regional recurrence for BC and CRC; current/former smoker for LC; high grade for CRC; and <4-year time-to-recurrence for BC.
conclusionsInitial stage predicts survival duration after recurrence, whereas time-to-recurrence usually does not. The impact of biologic characteristics (e.g., grade, hormone-receptor status) on survival duration after recurrence needs further study. Predictors of survival duration after recurrence may help facilitate patient decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.